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Abstract—We present the status and initial images of a
positron tomograph for prostate imaging that centers a
patient between a pair of external curved detector banks
(ellipse: 45 cm minor, 70 cm major axis). The distance between
detector banks adjusts to allow patient access and to position
the detectors as closely as possible for maximum sensitivity
with patients of various sizes. Each bank is composed of two
axial rows of 20 CTI PET Systems HR+ block detectors for a
total of 80 modules in the camera. Compared to an ECAT HR
PET system operating in 3D mode, our camera uses about one-
quarter the number of detectors and has approximately the
same sensitivity for a central point source, because our
detectors are close to the patient. The individual detectors are
angled in the plane to point towards the prostate to minimize
resolution degradation in that region. The detectors are read
out by modified CTI data acquisition electronics. We have
completed construction of the gantry and electronics, have
developed detector calibration and data acquisition software,
and are taking coincidence data. We demonstrate that we can
clearly visualize a “prostate” in a simple phantom.
Reconstructed images of two phantoms are shown.
I. INTRODUCTION
E present the development of a positron tomograph
optimized to image the prostate. This instrument
images radiopharmaceuticals that specifically localize in the
prostate to confirm the presence, absence or progression of
disease. It has approximately four times fewer detectors than
an ECAT HR or HR+ PET scanner, which will reduce the
cost and potentially increase clinical availability.
Prostate cancer has a prevalence and diagnostic rate similar
to breast cancer, with 230,000 new cases diagnosed in the
United States each year and one man in 6 diagnosed during
his lifetime. Prostate cancer suspicion is typically based on
an elevated prostate-specific antigen (PSA) level or a
suspicious mass found during a digital rectal exam.
Treatment decision is based mainly on biopsy confirmation
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of prostate cancer. Typical treatment options include
prostatectomy, external beam irradiation, brachytherapy
(interstitial implantation of radioactive seeds), androgen
ablation (hormone) therapy, or "watchful waiting." A major
problem with prostatic cancer therapy is the question of
where to biopsy, when to treat, or whether to treat at all. This
is particularly problematic in the case of an increased PSA
level with non-diagnostic repeated biopsies or after a
prostatectomy. A new imaging technology for sensitive
detection of prostate cancer is needed to confirm initial
diagnosis, guide biopsy and help guide treatment decisions.
In addition, a new method is needed to assess response
shortly after a treatment intervention.
In order to help meet these needs, we have built a PET
camera optimized to image the prostate. Functional PET
imaging will help detect malignant tumors in the prostate
and/or prostate bed as a follow-up for an elevated PSA level,
as well as possibly help determine tumor "aggressiveness"
based on metabolic uptake levels. Although not optimized to
detect distant metastatic disease, this PET camera should also
image local spread beyond the prostate bed to help guide
treatment decisions such as whether a narrow or wide
irradiation treatment field is needed.
Promising PET radiopharmaceuticals have recently
demonstrated outstanding results in the sensitive detection of
prostate cancer, inspiring a new interest in using PET for
prostate cancer imaging. Consistent with the evidence of
increased pool size of choline in prostate cancer [1, 2], Hara
and co-workers find that: [11C]choline clears the blood faster
than FDG; its uptake in prostate tumors is significantly
higher than in normal and surrounding tissues [3, 4],
providing excellent tumor/normal contrast; and bladder
accumulation is minimal if the correct time course is chosen
[5] which is a major advantage over FDG. Therefore,
[11C]choline is an attractive PET tracer for imaging primary
and metastatic tumors of the prostate and potentially for other
regions of the body [6-10]. Other 11C radiopharmaceuticals
are also under investigation for prostate cancer PET imaging,
including [11C]acetate and [11C]methionine.
18F imaging has the advantage of a longer half-life, which
increases clinical utility because an on-site cyclotron facility
would not be necessary (as it would for 11C imaging).
Although many groups have shown that PET imaging with
[18F]fluorodeoxyglucose (FDG) is not a good technique for
prostate cancer diagnosis, there are several other 18F
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radiopharmaceuticals currently under investigation including
[18F]fluorocholine (FCH) [11, 12]. PET images using
[18F]fluorocholine demonstrate high standardized uptake
values (e.g., SUV of 8), indicating that FCH is well
localized in the prostate cancer and can be imaged with good
resolution if short scan times (~five minutes) are used to
avoid bladder background.
II. CAMERA DESIGN
A. Overview
These new prostate tracers motivated us to build a low
cost PET camera optimized to image the prostate.
Coincidence imaging of positron emitters is achieved using a
pair of external curved detector banks, one placed above and
one below the patient. Fig. 1 shows the transaxial and
sagittal views of the camera. The bottom bank is fixed below
the patient bed, and the top bank moves upward for patient
access and downward for maximum sensitivity. Each bank
consists of two axial rows of 20 CTI ECAT HR+ block
detectors (80 detectors total in the camera), forming two arcs
with a minor axis of 45 cm and major axis of 70 cm. Our
prostate camera has about one-fourth the number of detectors
as an EXACT HR or HR+ because: (a) the patient is not
fully encircled in 2D, (b) an elliptical shape is used instead of
a circular one, and (c) the axial coverage is only 8 cm.
However, since the average distance to the detectors is
approximately one-half that of a conventional  PET system,
we expect to achieve improved detection efficiency at a lower
cost.
Individual detector modules are angled to point towards
the camera center near the prostate location in order to reduce
penetration effects (in the detector) for annihilation photons
originating in the prostate. This geometry increases
resolution selectively in the region of the prostate and is an
unique feature for a non-circular camera geometry.
Annihilation photons from other parts of the field of view
(FOV) will suffer increased penetration effects, but these
regions are less important. Both detector banks can be tilted
to image the prostate while minimizing attenuation (i.e.,
above the buttocks and below the stomach, see Fig. 1b), but
the gantry allows zero tilt for thin patients. A patient of
average size is not fully encircled in 2D, which results in
irregular and incomplete sampling due to the side gaps.
Despite this incomplete sampling, we are able to reconstruct
nearly artifact free images in the region of interest by using
an iterative reconstruction algorithm [13].
The camera design also includes shielding [13], as shown
in Fig. 1b. Inter-module septa extend 5 cm beyond the
scintillator crystals to reduce background events from random
coincidences and from photons that Compton scatter in the
patient [14]. These septa have not yet been built, so we have
operated in septa-less 3D mode for the data presented here.
Lead shields are used on the ends to reduce activity from
outside the field of view.
B. Electronics
Our camera uses modified commercial components in a
novel geometry. We use 80 CTI ECAT HR+ block detectors
that are three attenuation lengths thick for good detection
efficiency with narrow detector elements (i.e., 8 x 8 arrays of
4.5 x 4.5 x 30 mm3 BGO crystals) to achieve good spatial
resolution. We use modified front end, coincidence, and
readout electronics developed by CTI for the HRRT brain
imaging PET camera, as shown in Fig. 2. Since we are
creating a non-standard camera with HR+ and HRRT
components, a custom conversion board reroutes PMT
signals to electronics channel inputs. Events are detected and
assigned an arrival time, the crystal of interaction is
identified, energy qualification is performed, and a digital
word is formed using 28 CTI HRRT Analog Subsection
boards. The output signals from the Analog Subsection
boards are then multiplexed by six custom Detector Head
Interface (DHI) boards, which are based on the CTI HRRT
DHI design but each services a maximum of 15 (rather than
117) detector modules. We use six DHI boards to allow
coincidences between detector modules within the same bank
and plane. A CTI Coincidence Processor identifies singles
events in the different DHI boards that are in coincidence, and
the output is sent to a Pentium-based computer system for
reconstruction and display.
C. Gantry
The PET camera is complete except for the construction of
the septa. Fig. 3 shows a photograph of the camera with the
lead shielding on one side removed and a single row of
detector modules visible. Each detector module points toward
the center of the camera, as discussed in Section IIA. The
upper bank is mounted onto an aluminum back-plate whose
vertical motion is controlled using a hand-crank, allowing
upward movement for patient access and downward motion
to maximize sensitivity. A second hand-crank is used to
adjust the overall tilt of both upper and lower banks. The
readout electronics are mounted on the right housing (within
the Unistrut frame visible on the right in Fig. 3b). The six
DHI boards are mounted horizontally to the housing that
holds their corresponding Analog Subsection boards. The
Coincidence Processor board is mounted onto the cabinet
door for compactness. The ±5V and high voltage power
supplies are mounted on the left housing.
III. PERFORMANCE
A. Sensitivity and Count Rate
Coincidence event rates were measured by scanning a 1.5
mm diameter 120 µCi 68Ge point source along the central
axis of the patient port in 3 mm steps. A 270 keV energy
threshold was used for all measurements with a 22 nsec
coincidence timing window. Figure 4 shows the system
sensitivity as a function of axial position. The peak absolute
sensitivity is 1010 cps/µCi (2.7%) in 3D mode. This is
equivalent to the peak absolute sensitivity of the EXACT HR
in 3D mode and approximately 8 times higher than the
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EXACT HR in 2D mode, even though our camera has one-
quarter as many detectors.
The count rate as a function of activity density was
measured using a 19 cm inner diameter by 19 cm long
cylindrical phantom filled with 18F and centered in the
camera. Data were collected in 3D mode for 10 seconds every
20 minutes over a time span of 12 half-lives. Figure 5a
shows the count rate as a function of activity density for
total, prompt, random and true+scatter coincident events. The
maximum total count rate was 1.2 Mhz at an 1.5 µCi/ml
activity density. Figure 5b shows the count rate at only the
lower activity density corresponding to a standard clinical
range. The trues+scatter events cross the randoms at 0.23
µCi/ml.
B. Reconstruction Algorithm
We have developed a penalized maximum likelihood
reconstruction algorithm for the prostate camera. The
reconstruction software is designed to be very flexible in
modeling arbitrary scanner geometry. Forward and back
projections at each iteration are calculated using the exact
position and orientation of each detector block without any
rebinning. The crystal penetration effect is modeled using a
geometric calculation technique similar to that presented in
[15] for a positron emission mammography scanner. The
attenuation correction factors are calculated based on the
measured phantom geometry and a uniform attenuation
coefficient of 0.095/cm. A pixel size of 2 mm is used. We
estimate and subtract the random background using the
standard delayed window technique. The reconstruction
algorithm [13], including the normalization procedure, is not
yet final so we present only preliminary results.
C. Reconstructed Images
Rectangular planar phantoms are used for normalization.
Coincident data are acquired with a 27″ x 4″ x 0.375″ planar
phantom centered between the detector banks (i.e., placed
horizontally in Fig 3b), in order to correct for coincident
events that occur between detector banks. Coincident data are
acquired separately with a 10.6″ x 4″ x 0.375″ planar
phantom placed perpendicular to the 27″ phantom (i.e.,
placed vertically in Fig 3b), in order to correct for coincident
events that occur within the same detector bank.
Figure 6a shows a 37-point phantom. Single point sources
are placed 2, 4, 6 and 8 cm from the central point. Clusters
of 4 point sources are placed radially at 4 and 8 cm from the
central point, and the points in each cluster are spaced 8, 6, 5
and 4 mm apart. Figure 6b shows the preliminary
reconstructed image of this 37-point phantom when filled
with 18F at an initial activity of 0.6 mCi and imaged for two
minutes. Increased blurring is seen for point sources placed
further from the center. This blurring is primarily caused by
missing projections, because the crystal penetration effect is
modeled in the projection matrix. Minimal blurring is seen
in the 10 cm diameter central region. We are able to resolve
point sources that are separated by 4 mm when placed at a
diameter of 8 cm and 16 cm.
Figure 7a shows a concentric-cylinder phantom with three
times higher activity density in the inner cylinder than the
outer cylinder. Figure 7b shows the reconstructed image of
this phantom when filled with 18F at an initial total activity
density of 0.4 µCi/ml and imaged for four minutes. We can
clearly visualize a “prostate” in a simple phantom, when the
“prostate” has a three times higher activity density than the
“body.” Imperfect normalization factors result in some
noticeable streak artifacts. We expect the results to improve
once detector efficiency drifts have been minimized. Artifacts
at the top and bottom of the image are due to incomplete
sampling from the detector bank gaps.
IV. DISCUSSION
PET radiopharmaceuticals have recently demonstrated
promising results in the sensitive detection of prostate cancer.
Initially we plan to image using [11C]choline. In the future,
this camera can be used to evaluate new prostate cancer
radiopharmaceuticals. The high sensitivity of this new design
can achieve clinical imaging wherein short duration scans are
needed to avoid bladder background accumulation of tracers.
Accurate patient positioning is critical due to the limited
(8 cm) axial extent of the camera. The prostate is visible in
ultrasound images acquired with an external or trans-rectal
transducer, and we plan to use these images to position the
patient bed.
Finally, it is difficult to identify features other than the
prostate and the bladder in the PET images. Local anatomic
information is highly desirable to determine the location of
the disease within the prostate, as well as to determine
whether the disease has spread to the prostate bed. This
information could be obtained with dual modality imaging.
X-ray CT provides excellent images of the abdomen, but the
cost is relatively high. Ultrasound imaging with a trans-rectal
probe provides reasonable detail in the region of the prostate
and the cost of an ultrasound unit is significantly less than
that of a CT unit. We plan to explore adding co-registered
ultrasound imaging capability, including the use of dual
imaging for in situ guided biopsy.
V. CONCLUSION
Promising new PET tracers for prostate cancer, such as
[11C]choline and [11C]acetate, have motivated us to build a
PET camera optimized for prostate imaging. Reconstructed
images of extended and point source phantoms demonstrate
the feasibility of imaging prostate tumors with good spatial
resolution and image contrast at low cost relative to
commercial whole body PET scanners. The same sensitivity
as ECAT HR in 3D mode is achieved using only one-quarter
the number of detector modules and an axial length of 8 cm.
Before the camera is ready for patient imaging, we still need
to build the septa, automate the calibration procedure, finalize
the reconstruction algorithm, and characterize the camera
following NEMA performance measurements.
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(a)
Prostate
(b)
Fig. 1: Positron tomograph for prostate imaging. (a) Drawing of a transaxial
view through prostate, showing the patient centered between two detector
banks. The individual detector modules are angled to point towards the
prostate. No shielding is shown. (b) Drawing of the sagittal view. The
bottom arc is fixed below the patient bed, whereas the top arc adjusts
vertically for patient access and compactness. Both detector banks are
tilted and positioned as close as possible to the prostate, which improves
sensitivity and minimizes attenuation. The septa and lead shielding are
shown.
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Fig. 2: Diagram of the complete data collection chain, showing the custom
LBNL and CTI components and their inter-relations. The camera will use
80 CTI ECAT HR+ block detectors, 28 LBNL conversion boards, 28 CTI
HRRT Analog Subsection boards, 6 LBNL custom  Detector Head
Interface boards, 1 CTI Coincidence Processor and a PC.
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Fig. 3: (a) CTI ECAT HR+ detector module with an aluminum guide
epoxied along its midline (that is used to position and secure the module).
(b) Photograph of the partially-assembled camera with a single axial row of
detector modules visible. The detector modules are individually angled to
point towards the center of the camera. The gantry is now complete and
fully loaded with electronics and shielding. The camera is complete expect
for the septa.
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Fig. 4: System sensitivity as a function of axial position, using an 120 µCi
68Ge point source. Peak absolute sensitivity in the center of the field of
view is 1010 cps/µCi (2.7%) in 3D mode, which is the same as an EXACT
HR in 3D mode but with one-quarter as many detector modules. Data was
collected using a 270 keV energy threshold.
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Fig. 5: Count rate as a function of activity density for total, prompt, random
and true+scatter coincident events acquired with a cylindrical phantom (19
cm ID, 19 cm length) filled with 18F and centered in the camera. Plots show
two different ranges of activity density.
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Fig. 6: (a) Drawing of a cylindrical phantom (21 cm diameter, 5 cm axial)
with 37 point sources. The single point sources are 2, 4, 6, and 8 cm from
the central point. Clusters of 4 point sources are placed radially at 4 and 8
cm from the central point. The 4 point sources in each cluster are spaced 8,
6, 5, and 4 mm apart (clockwise from the 8 mm labeled clusters). (b)
Reconstructed image of the phantom using a preliminary iterative penalized
ML algorithm. Phantom was filled with 18F at an initial activity of 0.6 mCi
and imaged for 2 minutes. The central point was placed in the center of the
camera. Image represents 10 Mcounts. Axes are labeled in pixels (2 mm).
(a)
4 cm
19 cm  
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Fig. 7: (a) A concentric-cylinder phantom with three times higher activity
density in the central cylinder than the outer cylinder. (b) Preliminary
reconstructed image of the phantom using an iterative penalized ML
algorithm. Initial total 18F activity density was 0.4 µCi/ml and the imaging
time was 4 minutes. Image represents 78 Mcounts.
